Navigation Links
FDA Completes Work on Three Drug User Fee Programs
Date:1/13/2012

 As a result of the continued investment of PDUFA resources, the United States now leads the world in first introduction of novel drugs.

PDUFA was created by Congress in 1992 and must be reauthorized every five years. The current program, known as PDUFA IV, will expire on Sept. 30, 2012, unless reauthorized by Congress. FDA's recommendations for PDUFA V were developed in consultation both with drug industry representatives and with patient and consumer advocates.

Under the recommendations, fees paid by industry would support continued timely review of critical prescription drugs, as well as advance the development of drugs for rare diseases, provide for enhanced communication with small or emerging companies, increase the use of standardized electronic data to improve quality and efficiency, and foster the use of new clinical endpoints that improve drug development times and help address unmet medical needs.

The proposed new Generic Drug User Fee program would provide the FDA with needed funding at a time when generic drug applications are on the rise. Generic drug user fees would help ensure consumers timely access to safe, high-quality and effective generic drugs, which account for two-thirds of all prescriptions dispensed in the U.S.

The FDA receives 800 to 900 new generic-drug-related applications annually. These applications are increasingly complex and frequently involve products manufactured outside of the U.S. In exchange for fees on facilities and product applications, the proposal includes performance metrics such as review timeframes and a commitment to achieve parity between surveillance inspections of foreign and domestic establishments by the 2017 fiscal year. As a result, FDA expects that the proposal would effectively eliminate the review backlog and significantly reduce review times.

A biosimilar is a biological product that is highly similar to a U.S.-licensed reference biological product notwithstanding min
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Respironics, Inc. Completes Voluntary Recall Notification of a Limited Number of Trilogy 100 Ventilators
2. Quest Diagnostics Completes Acquisition of S.E.D. Medical Laboratories
3. Elevation Pharmaceuticals Completes $30 Million Series B Financing to Advance Aerosol COPD Therapy
4. Weikang Bio-technology Group, Inc. Completes HQ Relocation After Purchasing Building for $14 Million and Answers Questions About its Third Quarter Financials
5. Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock
6. Valeant Pharmaceuticals Completes Acquisition of iNova
7. Valeant Pharmaceuticals Completes Acquisition of Dermik
8. Vermillion Completes the Acquisition of Correlogic Systems Ovarian Cancer Diagnostics Business
9. Perceptive Informatics Completes Over 500 System Integrations as the Biopharma Industry Continues to Adopt Seamless eClinical Solutions
10. Sotera Wireless Completes $12.2 Million Series D Financing, Signs Agreement with Cerner
11. Concord Medical Completes its Twelfth Annual Academic Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... ANGELES , SINGAPORE, and TOKYO , ... announced that it has appointed Roger Crystal , ... most recently served in the Global Business Development Product ... "Roger,s experience in developing business strategy and ... valuable as we continue to partner with biotechnology and ...
(Date:7/28/2014)... 28, 2014  ANI Pharmaceuticals, Inc. (NASDAQ: ... release its second quarter and year-to-date 2014 financial results ... the U.S. financial markets. The earnings press release will ... Company,s website, www.anipharmaceuticals.com . Arthur ... Charlotte C. Arnold , Vice President and Chief ...
(Date:7/28/2014)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... Results and Highlights Conference CallWhen:Monday, August 4 at 10:30 ... on the Internet. Simply log onto our website listed ... live event, a replay of the webcast will be ... ABOUT ISIS PHARMACEUTICALS, INC. Isis is exploiting ...
Breaking Medicine Technology:ImaginAb Appoints Roger Crystal, MD as Vice President of Business Development 2ANI Pharmaceuticals Schedules Conference Call for Second Quarter 2014 Financial Results 2Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2
... Nov. 12 Based on its recent analysis ... & Sullivan presents Fovia, Inc. with the 2009 ... Innovation of the Year. Fovia is being recognized ... platform that offers unrivaled image quality and uncompromised ...
... Corporation (Nasdaq: THOR ), a world leader in ... restore failing hearts, said today that it will webcast ... II Destination Therapy clinical trial that will be presented ... American Heart Association(AHA) Scientific Sessions 2009. , The event ...
Cached Medicine Technology:Frost & Sullivan Recognizes Fovia for its HDVR(R) Platform - A Disruptive Technology Breakthrough 2Frost & Sullivan Recognizes Fovia for its HDVR(R) Platform - A Disruptive Technology Breakthrough 3Frost & Sullivan Recognizes Fovia for its HDVR(R) Platform - A Disruptive Technology Breakthrough 4
(Date:7/28/2014)... Mitul R. Patel, DDS and concerned ... MGE Management Experts Benefit Dinner May 30, in St. ... Dentists to raise funds for the Improving Youth Literacy ... and Youth Programs across America. The funds raised are ... and audio books to directly tackle illiteracy and help ...
(Date:7/28/2014)... Dr. Alan Xenakis, MD announced today the release ... The new book, DOC X MD Funny Feelings ... telling style with humor and medical accuracy. The book is ... find answers to those age-old questions that most folks are ... Why do mosquitoes bite some and not others? Why do ...
(Date:7/27/2014)... the leader in compression technology and sports medicine, has expanded ... The wrist support features an adjustable velcro strap and provides ... more commonly referred to as tennis elbow and golfers elbow, ... tendons attached to the outside of the elbow. Although this ... the wrist and fingers turn into a tendon that attaches ...
(Date:7/27/2014)... Manufacturers of natural ingredient beauty creams are ... a younger appearance. The Cherry News company has published ... and women explore the availabilities from U.S. retailers at ... in the posted guide on the Cherry News website ... drawback to some natural ingredient formulas is the high ...
(Date:7/27/2014)... of hepatitis E virus (HEV) transmission by blood components ... have HEV in their plasma. The findings, published in ... blood components (eg, red cells, platelets, and fresh frozen ... England. , The study retrospectively screened 225 000 ... Oct, 2012 and Sept, 2013 for HEV RNA. 79 ...
Breaking Medicine News(10 mins):Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 2Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 3Health News:New Book by Alan P. Xenakis, MD Reveals Mind and Body Mysteries 2Health News:Zensah® Releases New Wrist Support 2Health News:Natural Eye Cream Buyer's Guide Published Online at Consumer News Website 2Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2
... Roughly 15% of children suffer from migraines, and approximately one-third ... of symptoms that can include weakness, blind spots, and even ... new study soon to be published in The Journal ... children and a heart defect called patent foramen ovale, which ...
... cells in the intestine, which when they mutate can lead ... to combat the effects of those same cancers, the UK ... today. Professor Nick Barker of the Institute of Medical ... identified that the stem cells which are crucial to maintaining ...
... Commons, an initiative of CollabRx, a provider of ... research, announces the publication of a molecular disease ... into molecular subtypes, rather than traditional histological or ... subtype, including specific assays, drugs, and clinical trials. ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, March ... U.S. Food and Drug Administration (FDA) is meeting Wednesday and ... used food dyes and attention-deficit/hyperactivity disorder (ADHD), and if so, ... industry against some parents, public watchdog groups and academics who,ve ...
... HealthDay Reporter , WEDNESDAY, March 30 (HealthDay News) -- ... nursing homes, a new study shows. Researchers say the ... lead to improvements in patient care. Nor does it appear ... in terms of fewer lawsuits. "Nursing homes that are ...
... for Maternal-Fetal Medicine (SMFM) weighed in on today,s FDA ... caproate, also known as 17P. This FDA announcement ... and others regarding the costs of the just-released pharmaceutical ... made by KV Pharmaceuticals, is being sold at $1,500 ...
Cached Medicine News:Health News:Attacking bowel cancer on 2 fronts 2Health News:Researchers publish molecular disease model for melanoma 2Health News:Researchers publish molecular disease model for melanoma 3Health News:FDA Panel Examines Possible Links Between Food Dyes, ADHD 2Health News:FDA Panel Examines Possible Links Between Food Dyes, ADHD 3Health News:FDA Panel Examines Possible Links Between Food Dyes, ADHD 4Health News:Lawsuits Aren't Improving Nursing Home Care: Study 2Health News:Lawsuits Aren't Improving Nursing Home Care: Study 3Health News:Lawsuits Aren't Improving Nursing Home Care: Study 4Health News:Society for Maternal-Fetal Medicine commends FDA on makena announcement 2
... the challenge of,controlling costs while handling ... data,management is critical. INFINITY modular,patient monitors ... clinical information,wherever you are in the ... your job easier. You can monitor,your ...
... The biograph 6 offers ... improved disease diagnosis and treatment ... It delivers high-quality PET/CT whole ... 15 minutes. Our comprehensive suite ...
... offers the ultimate PET/CT performance ... treatment in oncology, neurology, and ... whole body scans in less ... suite of clinical applications offers ...
... Duo is a SmartBeam platform providing high-performance ... of the two most clinical sites - ... at a low radiation dose., ,The ... Windows, optimizes productivity and ensures consistant results. ...
Medicine Products: